Compounded oral GLP-1 tablets

A dissolvable tablet rather than an injection. The tablet program covers both of the molecules offered here, and your provider decides which one you are prescribed.

Covering both molecules is not pricing them the same. The tablet price this site shows is for semaglutide; tirzepatide on the tablet program is priced separately, so which one you are prescribed changes what you pay. The pricing page carries the figures.

It is the option for people whose objection to the injectables is the injection itself.

FDA says compounded drugs should only be used in patients whose medical needs cannot be met by an FDA-approved drug, and that compounded drugs are not FDA approved — the agency does not review them for safety, effectiveness or quality before they are marketed. U.S. Food and Drug Administration, 2026-09-01

As of 31 May 2026 FDA had received 990 reports of adverse events associated with compounded semaglutide and more than 730 associated with compounded tirzepatide, and it says these are likely underreported, because federal law does not require state-licensed pharmacies that are not outsourcing facilities to report them. FDA also says it is not always possible to determine whether an adverse event resulted directly from use of the drug, or whether other factors contributed to it. U.S. Food and Drug Administration, 2026-09-01

FDA says it is aware of fraudulent compounded semaglutide and tirzepatide marketed in the U.S. that carry false information on the product label: in some cases the compounding pharmacies named on the label do not exist, and in others the label names a licensed pharmacy that, on the information FDA has gathered, did not compound the product. One reported adverse event involved a product labelled as compounded tirzepatide from a pharmacy that did not actually compound it. U.S. Food and Drug Administration, 2026-09-01

FDA has established a green list import alert to help stop GLP-1 active pharmaceutical ingredients that have potential quality concerns from entering the U.S. supply chain, which it says will help protect consumers from receiving poor-quality compounded drugs containing foreign-made ingredients that may be manufactured without appropriate controls to assure quality. U.S. Food and Drug Administration, 2026-09-01

FDA has said that semaglutide salt forms, such as semaglutide sodium and semaglutide acetate, are different active ingredients from the one used in the approved drugs, that it has no information on whether those salts share the same chemical and pharmacologic properties, and that it is not aware of any lawful basis for their use in compounding. U.S. Food and Drug Administration, 2026-09-01

Daily rather than weekly is the practical difference to plan around: it is a habit rather than an appointment with yourself once a week. Take what you are dispensed as its label and your provider direct — and if the two disagree, or anything on the label looks wrong, ask before you take it rather than resolving it yourself.

FDA has also received adverse event reports that may relate to patients prescribed compounded semaglutide or tirzepatide in doses beyond what is in the FDA-approved label — more in a single dose, doses more often, or a faster titration schedule. Some of those events are serious. U.S. Food and Drug Administration, 2026-09-01

Tablets are easy to buy from anyone, which is exactly why the regulator has published what a legitimate route looks like and what the warning signs are.

FDA advises obtaining a prescription from a doctor and filling it at a state-licensed pharmacy, and names seven warning signs for a telehealth seller: claims that the compounded drug is the same as an FDA-approved drug; medicine offered at deep discounts or at prices that seem too good to be true; medicine that looks different from what you have previously received or from what was pictured, or that arrives in packaging that is broken or damaged or lacks instructions for use; no screening and prescription by a licensed doctor before medicine is provided; no licensed doctor available to answer questions after you receive your medication; spelling errors on the label or incorrect addresses for the pharmacy; and a pharmacy name on the label that you think might be fraudulent. U.S. Food and Drug Administration, 2026-09-01

FDA recommends contacting the compounder that made a drug, or the telehealth platform it was bought from, with any question about its label or its instructions for use. U.S. Food and Drug Administration, 2026-09-01